Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib in Phase 3 Studies for Rheumatoid Arthritis

Gilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.

Read More »

Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals

Swiss drugmakers Novartis and Lonza separately deepened the companies’ push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.

Read More »

Lilly Receives U.S. FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis

The FDA approved Eli Lilly and Co.’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

Read More »

J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June 2019 as part of an investigation into whether contracting practices for the blockbuster rheumatoid arthritis drug Remicade violated antitrust laws, the company said in a regulatory filing.

Read More »

British Columbia to be first Canadian province to switch patients to biosimilars

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Read More »

Novartis 2019 growth outlook leaves investors wanting more

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Read More »

Merck’s Frazier to remain CEO of the U.S. drugmaker beyond 2019

Merck & Co. Inc. Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019 after scrapping a policy requiring the drugmaker’s CEOs to retire at the age of 65.

Read More »

Fewer U.S. adults getting unnecessary knee surgery

So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.

Read More »

With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval

Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.

Read More »

Selecta Unveils Expanded Positive Clinical Data for Gout Treatment

Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage study that showed a significant reduction of serum uric acid at 12 weeks.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom